|
Aug 6
|
Snap downgraded, Leidos upgraded: Wall Street's top analyst calls
|
|
Aug 6
|
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
|
|
Aug 5
|
Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis
|
|
Aug 4
|
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
|
|
Aug 1
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
Aug 1
|
Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls
|
|
Jul 31
|
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil
|
|
Jul 25
|
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
|
|
Jul 24
|
Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
|
|
Jul 24
|
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
|
|
Jul 16
|
INCY or TECH: Which Is the Better Value Stock Right Now?
|
|
Jul 14
|
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement
|
|
Jul 11
|
High Growth Tech Stocks To Watch In US July 2025
|
|
Jul 2
|
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 1
|
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
|
|
Jun 30
|
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
|
|
Jun 27
|
Incyte Stock Gets Relative Strength Rating Lift
|
|
Jun 27
|
Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz
|
|
Jun 26
|
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
|
|
Jun 26
|
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
|